Skip to main content
MADRIGAL PHARMACEUTICALS, INC. logo

MADRIGAL PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · MDGL ISIN · US5588681057 LEI · 549300CHIMT2EUSNJB60 US Manufacturing
Open in API
Filings indexed 1,022 across all filing types
Latest filing 2019-07-01 Director's Dealing
Country US United States of America
Listing US MDGL

About MADRIGAL PHARMACEUTICALS, INC.

https://www.madrigalpharma.com/

Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious and progressive liver disease with high unmet medical need. The company's research led to the first U.S. Food and Drug Administration (FDA)-approved treatment for MASH. Madrigal's therapeutic goal is to halt or reverse liver scarring (fibrosis) and resolve the disease before patients experience severe complications, including cirrhosis, liver failure, and the need for transplantation.

Recent filings

Filing Released Lang Actions
FORM 4 SUBMISSION
Director's Dealing
2019-07-01 English
FORM 4 SUBMISSION
Director's Dealing
2019-07-01 English
FORM 4 SUBMISSION
Director's Dealing
2019-07-01 English
DEFA14A
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a Schedule 14A filing, which is a Proxy Statement filed pursuant to Section 14(a) of the Securities Exchange Act of 1934. It includes details about the Annual Meeting, proposals to be voted on, and instructions for accessing proxy materials. It is labeled as 'Definitive Additional Materials' related to the proxy statement. The content focuses on soliciting shareholder votes and providing information about the meeting agenda, including election of directors and approval of compensation plans. This matches the definition of Proxy Solicitation & Information Statement (PSI). The document length is under 5,000 characters but contains substantive proxy solicitation content, not just an announcement of availability, so it is not a Report Publication Announcement (RPA). Therefore, the correct classification is PSI with high confidence.
2019-05-15 English
DEF 14A
Proxy Solicitation & Information Statement
2019-05-15 English
FORM 3 SUBMISSION
Director's Dealing
2019-05-09 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.